Roope Laurence S J, Morrell Liz, Buchanan James, Ledda Alice, Adler Amanda I, Jit Mark, Walker A Sarah, Pouwels Koen B, Robotham Julie V, Wordsworth Sarah
Health Economics Research Centre, Nuffield Department of Population Health, University of Oxford, Oxford, UK.
NIHR Oxford Biomedical Research Centre, John Radcliffe Hospital, University of Oxford, Oxford, UK.
Commun Med (Lond). 2024 May 25;4(1):101. doi: 10.1038/s43856-024-00516-9.
Bacteria are becoming increasingly resistant to antibiotics, reducing our ability to treat infections and threatening to undermine modern health care. Optimising antibiotic use is a key element in tackling the problem. Traditional economic evaluation methods do not capture many of the benefits from improved antibiotic use and the potential impact on resistance. Not capturing these benefits is a major obstacle to optimising antibiotic use, as it fails to incentivise the development and use of interventions to optimise the use of antibiotics and preserve their effectiveness (stewardship interventions). Estimates of the benefits of improving antibiotic use involve considerable uncertainty as they depend on the evolution of resistance and associated health outcomes and costs. Here we discuss how economic evaluation methods might be adapted, in the face of such uncertainties. We propose a threshold-based approach that estimates the minimum resistance-related costs that would need to be averted by an intervention to make it cost-effective. If it is probable that without the intervention costs will exceed the threshold then the intervention should be deemed cost-effective.
细菌对抗生素的耐药性日益增强,这削弱了我们治疗感染的能力,并有可能破坏现代医疗保健体系。优化抗生素使用是解决这一问题的关键要素。传统的经济评估方法未能涵盖优化抗生素使用所带来的诸多益处以及对耐药性的潜在影响。未能捕捉到这些益处是优化抗生素使用的一个主要障碍,因为这无法激励开发和采用干预措施来优化抗生素的使用并保持其有效性(管理干预措施)。改善抗生素使用的益处评估存在相当大的不确定性,因为它们取决于耐药性的演变以及相关的健康结果和成本。在此,我们讨论面对此类不确定性时经济评估方法应如何调整。我们提出一种基于阈值 的方法,该方法估计一项干预措施为具有成本效益而需要避免的与耐药性相关的最低成本。如果很可能在没有该干预措施的情况下成本将超过阈值,那么该干预措施应被视为具有成本效益。